About this Research Topic
Hypertension is a leading cause of various types of cardiovascular diseases (CVD) including heart failture (HF) and chronic kidney disease(CKD). However, achieving appropriate blood pressure (BP) reduction for cardio-renal protection has not always been successful in real-world clinical practice. Therapies to reduce BP using sacubitril/valsartan (ARNI) has been reported as efficacious in patients with HF with reduced ejection fraction. However, the renoprotective effect of ARNI has not fully been analyzed. In the meantime, it is evident that combining multiple antihypertensive agents with different modes of actions can be useful to achieve a better BP control. In this context, treatment with ARNI may be anticipated to fulfill this purpose. Currently, the evaluation of ARNI in terms of renal effects is still scant and insufficient.
The goal of this Research Topic is to gain insights into the renal protective effect of ARNI in patients with CKD complicated by either HF or hypertension. While it may be premature to draw a conclusion, we aim to explore this unknown theme by introducing the “Pros and Cons” debate regarding the renal effect of ARNI in relation to cardiorenal syndrome.
We welcome submissions focusing on, but not limited to, the following subtopics:
• Describe cardio-renal syndrome where most of the patient may suffer from CKD.
• Highlight the unique physiological natriuretic properties of NP containing ARNI
• Investigate the basic and clinical effect of NP (plus ARB, Valsartan)
• Explore the use of ARNI in managing hypertension as well as HF
• Cardio-Renal continuum in heart failure (HF) and CKD patients
• Pharmacological characteristics and the pathophysiological roles of Natriuretic Peptides (NP) in patients with HF and CKD
• Potential mechanisms of the cardio-renal protection with ARNI from both basic and clinical perspectives.
• Analyze the antihypertensive effect and mechanisms of ARNI in patients with hypertensive CKD
• Future therapeutic implications of ARNI treatment
The goal of this Research Topic is to gain insights into the renal protective effect of ARNI in patients with CKD complicated by either HF or hypertension. While it may be premature to draw a conclusion, we aim to explore this unknown theme by introducing the “Pros and Cons” debate regarding the renal effect of ARNI in relation to cardiorenal syndrome.
We welcome submissions focusing on, but not limited to, the following subtopics:
• Describe cardio-renal syndrome where most of the patient may suffer from CKD.
• Highlight the unique physiological natriuretic properties of NP containing ARNI
• Investigate the basic and clinical effect of NP (plus ARB, Valsartan)
• Explore the use of ARNI in managing hypertension as well as HF
• Cardio-Renal continuum in heart failure (HF) and CKD patients
• Pharmacological characteristics and the pathophysiological roles of Natriuretic Peptides (NP) in patients with HF and CKD
• Potential mechanisms of the cardio-renal protection with ARNI from both basic and clinical perspectives.
• Analyze the antihypertensive effect and mechanisms of ARNI in patients with hypertensive CKD
• Future therapeutic implications of ARNI treatment
Keywords: sacubitril/valsartan (ARNI), hypertension, chronic kidney disease (CKD), heart failure
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
